{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:16:28Z","timestamp":1791918988330,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,11]]},"DOI":"10.7759\/cureus.17093","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T13:44:55Z","timestamp":1628689495000},"source":"Crossref","is-referenced-by-count":7,"title":["Sodium-Glucose Co-transporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis After Bariatric Surgery: A Case and Literature Review"],"prefix":"10.7759","author":[{"given":"Vaishali","family":"Kapila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Topf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5866.578","article-title":"Euglycaemic diabetic ketoacidosis","volume":"2","author":"Munro JF","year":"1973","unstructured":"Munro JF, Campbell IW, McCuish AC, Duncan LJ. Euglycaemic diabetic ketoacidosis. Br Med J. 1973, 2:578-80. 10.1136\/bmj.2.5866.578","journal-title":"Br Med J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2174\/1573399812666160421121307","article-title":"Euglycemic diabetic ketoacidosis: a review","volume":"13","author":"Modi A","year":"2017","unstructured":"Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a review. Curr Diabetes Rev. 2017, 13:315-21. 10.2174\/1573399812666160421121307","journal-title":"Curr Diabetes Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, DeMets DL, Inzucchi SE, et al.. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019, 21:665-75. 10.1002\/ejhf.1432","journal-title":"Eur J Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S184437","article-title":"Canagliflozin review - safety and efficacy profile in patients with T2DM","volume":"12","author":"Jakher H","year":"2019","unstructured":"Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes. 2019, 12:209-215. 10.2147\/DMSO.S184437","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref10","article-title":"Risks vs benefits for SGLT2 inhibitor medications","volume":"35","author":"Pittampalli S","year":"2018","unstructured":"Pittampalli S, Upadyayula S, Mekala HM, Lippmann S. Risks vs benefits for SGLT2 inhibitor medications. Fed Pract. 2018, 35:45-8.","journal-title":"Fed Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12245-019-0240-0","article-title":"Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature","volume":"12","author":"Diaz-Ramos A","year":"2019","unstructured":"Diaz-Ramos A, Eilbert W, Marquez D. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature. Int J Emerg Med. 2019, 12:27. 10.1186\/s12245-019-0240-0","journal-title":"Int J Emerg Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock J","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015, 38:1638-42. 10.2337\/dc15-1380","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2924","article-title":"Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data","volume":"33","author":"Blau JE","year":"2017","unstructured":"Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev. 2017, 33:e2924. 10.1002\/dmrr.2924","journal-title":"Diabetes Metab Res Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2017.10.001","article-title":"Euglycemic diabetic ketoacidosis secondary to dapagliflozin use: a\u00a0case report","volume":"54","author":"Brown F","year":"2018","unstructured":"Brown F, McColl T. Euglycemic diabetic ketoacidosis secondary to dapagliflozin use: a\u00a0case report. J Emerg Med. 2018, 54:109-11. 10.1016\/j.jemermed.2017.10.001","journal-title":"J Emerg Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000152","article-title":"Sodium-glucose cotransport","volume":"24","author":"Poulsen SB","year":"2015","unstructured":"Poulsen SB, Fenton RA, Rieg T. Sodium-glucose cotransport. Curr Opin Nephrol Hypertens. 2015, 24:463-9. 10.1097\/MNH.0000000000000152","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa W","year":"2016","unstructured":"Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016, 7:135-8. 10.1111\/jdi.12401","journal-title":"J Diabetes Investig"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2174\/1871529X18666180206123149","article-title":"Sodium-glucose cotransporter 2 inhibitors and the risk of diabetic ketoacidosis; from pathophysiology to clinical practice","volume":"18","author":"Patoulias D","year":"2018","unstructured":"Patoulias D, Manafis A, Mitas C, et al.. Sodium-glucose cotransporter 2 inhibitors and the risk of diabetic ketoacidosis; from pathophysiology to clinical practice. Cardiovasc Hematol Disord Drug Targets. 2018, 18:139-46. 10.2174\/1871529X18666180206123149","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.REV120.008387","article-title":"Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks","volume":"295","author":"Perry RJ","year":"2020","unstructured":"Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020, 295:14379-90. 10.1074\/jbc.REV120.008387","journal-title":"J Biol Chem"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.nutres.2018.11.007","article-title":"Weight loss, improved physical performance, cognitive function, eating behavior, and metabolic profile in a 12-week ketogenic diet in obese adults","volume":"62","author":"Mohorko N","year":"2019","unstructured":"Mohorko N, \u010cerneli\u010d-Bizjak M, Poklar-Vatovec T, Grom G, Kenig S, Petelin A, Jenko-Pra\u017enikar Z. Weight loss, improved physical performance, cognitive function, eating behavior, and metabolic profile in a 12-week ketogenic diet in obese adults. Nutr Res. 2019, 62:64-77. 10.1016\/j.nutres.2018.11.007","journal-title":"Nutr Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-6-21","article-title":"Effects of a low-carbohydrate diet on glycemic control in outpatients with severe type 2 diabetes","volume":"6","author":"Haimoto H","year":"2009","unstructured":"Haimoto H, Sasakabe T, Wakai K, Umegaki H. Effects of a low-carbohydrate diet on glycemic control in outpatients with severe type 2 diabetes. Nutr Metab (Lond). 2009, 6:21. 10.1186\/1743-7075-6-21","journal-title":"Nutr Metab (Lond)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/nu9050517","article-title":"Effects of ketogenic diets on cardiovascular risk factors: evidence from animal and human studies","volume":"9","author":"Kosinski C","year":"2017","unstructured":"Kosinski C, Jornayvaz FR. Effects of ketogenic diets on cardiovascular risk factors: evidence from animal and human studies. Nutrients. 2017, 9:517. 10.3390\/nu9050517","journal-title":"Nutrients"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/nu11050962","article-title":"Low-carb and ketogenic diets in type 1 and type 2 diabetes","volume":"11","author":"Bolla AM","year":"2019","unstructured":"Bolla AM, Caretto A, Laurenzi A, Scavini M, Piemonti L. Low-carb and ketogenic diets in type 1 and type 2 diabetes. Nutrients. 2019, 11:962. 10.3390\/nu11050962","journal-title":"Nutrients"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph110202092","article-title":"Ketogenic diet for obesity: friend or foe?","volume":"11","author":"Paoli A","year":"2014","unstructured":"Paoli A. Ketogenic diet for obesity: friend or foe?. Int J Environ Res Public Health. 2014, 11:2092-107. 10.3390\/ijerph110202092","journal-title":"Int J Environ Res Public Health"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2016.03.020","article-title":"Hyperketonemia and ketosis increase the risk of complications in type 1 diabetes","volume":"95","author":"Kanikarla-Marie P","year":"2016","unstructured":"Kanikarla-Marie P, Jain SK. Hyperketonemia and ketosis increase the risk of complications in type 1 diabetes. Free Radic Biol Med. 2016, 95:268-77. 10.1016\/j.freeradbiomed.2016.03.020","journal-title":"Free Radic Biol Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2337\/cd20-0001","article-title":"Ketogenic diet as a trigger for diabetic ketoacidosis in a misdiagnosis of diabetes: a case report","volume":"38","author":"White-Cotsmire AJ","year":"2020","unstructured":"White-Cotsmire AJ, Healy AM. Ketogenic diet as a trigger for diabetic ketoacidosis in a misdiagnosis of diabetes: a case report. Clin Diabetes. 2020, 38:318-21. 10.2337\/cd20-0001","journal-title":"Clin Diabetes"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4158\/ACCR-2020-0314","article-title":"Successful reimplementation of a very low carbohydrate ketogenic diet after SGLT2 inhibitor associated euglycemic diabetic ketoacidosis","volume":"6","author":"Fieger EI","year":"2020","unstructured":"Fieger EI, Fadel KM, Modarres AH, Wickham EP 3rd, Wolver SE. Successful reimplementation of a very low carbohydrate ketogenic diet after SGLT2 inhibitor associated euglycemic diabetic ketoacidosis. AACE Clin Case Rep. 2020, 6:e330-3. 10.4158\/ACCR-2020-0314","journal-title":"AACE Clin Case Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12246","article-title":"Profound hypokalemia associated with severe diabetic ketoacidosis","volume":"17","author":"Davis SM","year":"2016","unstructured":"Davis SM, Maddux AB, Alonso GT, Okada CR, Mourani PM, Maahs DM. Profound hypokalemia associated with severe diabetic ketoacidosis. Pediatr Diabetes. 2016, 17:61-5. 10.1111\/pedi.12246","journal-title":"Pediatr Diabetes"},{"key":"ref28","unstructured":"FDA drug safety communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warning about too much acid in the blood and serious urinary tract infections. (2020). Accessed. November 8, 2020: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-...."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne T","year":"2019","unstructured":"Danne T, Garg S, Peters AL, et al.. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019, 42:1147-54. 10.2337\/dc18-2316","journal-title":"Diabetes Care"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1089\/pancan.2018.0016","article-title":"Euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy","volume":"4","author":"Pace DJ","year":"2018","unstructured":"Pace DJ, Dukleska K, Phillips S, Gleason V, Yeo CJ. Euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy. J Pancreat Cancer. 2018, 4:95-9. 10.1089\/pancan.2018.0016","journal-title":"J Pancreat Cancer"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1721","article-title":"SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications","volume":"41","author":"Meyer EJ","year":"2018","unstructured":"Meyer EJ, Gabb G, Jesudason D. SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care. 2018, 41:e47-9. 10.2337\/dc17-1721","journal-title":"Diabetes Care"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10078","article-title":"Sodium-glucose linked transporter inhibitors as a cause of euglycemic diabetic ketoacidosis on a background of starvation","volume":"12","author":"Tauseef A","year":"2020","unstructured":"Tauseef A, Asghar MS, Zafar M, Lateef N, Thirumalareddy J. Sodium-glucose linked transporter inhibitors as a cause of euglycemic diabetic ketoacidosis on a background of starvation. Cureus. 2020, 12:e10078. 10.7759\/cureus.10078","journal-title":"Cureus"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8832833","article-title":"A case of diabetic ketoacidosis in a patient on an SGLT2 Inhibitor and a ketogenic diet: a critical trio not to be missed","volume":"2020","author":"Steinmetz-Wood S","year":"2020","unstructured":"Steinmetz-Wood S, Gilbert M, Menson K. A case of diabetic ketoacidosis in a patient on an SGLT2 Inhibitor and a ketogenic diet: a critical trio not to be missed. Case Rep Endocrinol. 2020, 2020:8832833. 10.1155\/2020\/8832833","journal-title":"Case Rep Endocrinol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10199","article-title":"Euglycemic diabetic ketoacidosis precipitated by a keto diet: importance of dietary history in diagnosis","volume":"12","author":"Shaikh S","year":"2020","unstructured":"Shaikh S, Mohamed MM, Mujeeb A, Shaikh F, Harris B. Euglycemic diabetic ketoacidosis precipitated by a keto diet: importance of dietary history in diagnosis. Cureus. 2020, 12:e10199. 10.7759\/cureus.10199","journal-title":"Cureus"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/ams2.480","article-title":"Euglycemic diabetic ketoacidosis due to a strict low-carbohydrate diet during treatment with sodium-glucose cotransporter 2 inhibitors","volume":"7","author":"Fukuyama Y","year":"2020","unstructured":"Fukuyama Y, Numata K, Yoshino K, Santanda T, Funakoshi H. Euglycemic diabetic ketoacidosis due to a strict low-carbohydrate diet during treatment with sodium-glucose cotransporter 2 inhibitors. Acute Med Surg. 2020, 7:e480. 10.1002\/ams2.480","journal-title":"Acute Med Surg"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55080462","article-title":"Nephrology consultation for severe SGLT2 inhibitor-induced ketoacidosis in type 2 diabetes: case report","volume":"55","author":"Nappi F","year":"2019","unstructured":"Nappi F, La Verde A, Carfora G, Garofalo C, Provenzano M, Sasso FC, De Nicola L. Nephrology consultation for severe SGLT2 inhibitor-induced ketoacidosis in type 2 diabetes: case report. Medicina (Kaunas). 2019, 55:462. 10.3390\/medicina55080462","journal-title":"Medicina (Kaunas)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2011.01.002","article-title":"Prevalence of hypokalemia in ED patients with diabetic ketoacidosis","volume":"30","author":"Arora S","year":"2012","unstructured":"Arora S, Cheng D, Wyler B, Menchine M. Prevalence of hypokalemia in ED patients with diabetic ketoacidosis. Am J Emerg Med. 2012, 30:481-4. 10.1016\/j.ajem.2011.01.002","journal-title":"Am J Emerg Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2013.10.024","article-title":"Sporadic hypokalemic paralysis caused by osmotic diuresis in diabetes mellitus","volume":"21","author":"Vishnu VY","year":"2014","unstructured":"Vishnu VY, Kattadimmal A, Rao SA, Kadhiravan T. Sporadic hypokalemic paralysis caused by osmotic diuresis in diabetes mellitus. J Clin Neurosci. 2014, 21:1267-8. 10.1016\/j.jocn.2013.10.024","journal-title":"J Clin Neurosci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1053\/jcrc.2002.36755","article-title":"Predictors of intensive care unit and hospital length of stay in diabetic ketoacidosis","volume":"17","author":"Freire AX","year":"2002","unstructured":"Freire AX, Umpierrez GE, Afessa B, Latif KA, Bridges L, Kitabchi AE. Predictors of intensive care unit and hospital length of stay in diabetic ketoacidosis. J Crit Care. 2002, 17:207-11. 10.1053\/jcrc.2002.36755","journal-title":"J Crit Care"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1379","article-title":"Health care utilization and burden of diabetic ketoacidosis in the U.S. over the past decade: a nationwide analysis","volume":"41","author":"Desai D","year":"2018","unstructured":"Desai D, Mehta D, Mathias P, Menon G, Schubart UK. Health care utilization and burden of diabetic ketoacidosis in the U.S. over the past decade: a nationwide analysis. Diabetes Care. 2018, 41:1631-8. 10.2337\/dc17-1379","journal-title":"Diabetes Care"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2019.01.001","article-title":"Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors","volume":"45","author":"Jeon JY","year":"2019","unstructured":"Jeon JY, Kim SK, Kim KS, et al.. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors. Diabetes Metab. 2019, 45:453-7. 10.1016\/j.diabet.2019.01.001","journal-title":"Diabetes Metab"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-235969","article-title":"Prolonged euglycemic diabetic ketoacidosis triggered by a single dose of sodium-glucose cotransporter 2 inhibitor","volume":"13","author":"Miwa M","year":"2020","unstructured":"Miwa M, Nakajima M, Kaszynski RH, Goto H. Prolonged euglycemic diabetic ketoacidosis triggered by a single dose of sodium-glucose cotransporter 2 inhibitor. BMJ Case Rep. 2020, 13:e235969. 10.1136\/bcr-2020-235969","journal-title":"BMJ Case Rep"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0087","article-title":"Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis","volume":"2019","author":"Rafey MF","year":"2019","unstructured":"Rafey MF, Butt A, Coffey B, Reddington L, Devitt A, Lappin D, Finucane FM. Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis. Endocrinol Diabetes Metab Case Rep. 2019, 2019:10.1530\/EDM-19-0087","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4384","article-title":"Euglycemic diabetic ketoacidosis in the setting of SGLT2 inhibitor use and hypertriglyceridemia: a case report and review of literature","volume":"11","author":"Gajjar K","year":"2019","unstructured":"Gajjar K, Luthra P. Euglycemic diabetic ketoacidosis in the setting of SGLT2 inhibitor use and hypertriglyceridemia: a case report and review of literature. Cureus. 2019, 11:e4384. 10.7759\/cureus.4384","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/67325-sodium-glucose-co-transporter-2-inhibitor-associated-euglycemic-diabetic-ketoacidosis-after-bariatric-surgery-a-case-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:03Z","timestamp":1707506943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/67325-sodium-glucose-co-transporter-2-inhibitor-associated-euglycemic-diabetic-ketoacidosis-after-bariatric-surgery-a-case-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.17093","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,11]]}}}